Rigel Pharmaceuticals, Inc. (RIGL) Competitors & Peers
The 5 largest companies in the same industry as Rigel Pharmaceuticals, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $526.19 | P/E 30.2RSI 51Cap 133.4 B |
| REGN | Peer | $788.04 | P/E 19.5RSI 48Cap 81.1 B |
| ARGX | Peer | $959.49 | P/E 36.5RSI 45Cap 60.0 B |
| RVMD | Peer | $204.97 | RSI 41Cap 41.4 B |
| ALNY | Peer | $255.96 | P/E 44.6RSI 56Cap 34.2 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- AZNSupplier
Own 10-K customer-concentration disclosure: AstraZenecaAB = 100% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - LLYSupplier
Own 10-K customer-concentration disclosure: ElyLillyAndCompany = 48% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CAHSupplier
Own 10-K customer-concentration disclosure: CardinalHealthInc = 13% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
Own 10-K customer-concentration disclosure: MckessonSpecialtyCareDistributionCorporation = 45% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - 4547.TSupplier
Own 10-K customer-concentration disclosure: KisseiPharmaceuticalCo.Ltd. = 11% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MRKSupplier
Own 10-K customer-concentration disclosure: MerckSeronoSA = 89% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - DSNKYSupplier
Own 10-K customer-concentration disclosure: DaiichiSankyo = 2% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - ACRSSupplier
Own 10-K customer-concentration disclosure: AclarisTherapeutics = 9% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - GRFSupplier
Own 10-K customer-concentration disclosure: GrifolsS.a. = 41% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- IQVPartner
IQVIA provides contract clinical research and trial management services (CRO).
Model-inferred, unverified — treat as a lead, not evidence - AMZNSupplier
Utilizes AWS cloud infrastructure to host genomic sequencing data and clinical trial databases.
Model-inferred, unverified — treat as a lead, not evidence - PFECompetitor
Competes in development and commercialization of therapeutics for similar indications.
Model-inferred, unverified — treat as a lead, not evidence